Patents by Inventor Klaus-Peter Radtke
Klaus-Peter Radtke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240092828Abstract: Systems are provided for isolation of a protein, such as immunoglobulin G (IgG), from plasma, where the protein is initially fractioned by salt precipitation, followed by successive ion exchange steps in which the protein appears in unbound, flow-through fractions of the ion exchange steps. Some embodiments employ successive anion exchange steps. Other embodiments employ an anion exchange step followed by application of flow-through of the anion exchange step to a cation exchange step, with the protein collected in flow-through fractions from the cation exchange step. IgG is collected at high yield (typically about 75% or greater) and high purity. Avoidance of binding and elution from chromatography media simplifies processing and scale up without sacrificing IgG quality or yield.Type: ApplicationFiled: November 21, 2023Publication date: March 21, 2024Inventors: Eugene Zurlo, Dennis Curtin, Klaus Peter Radtke, Ryan Dorfman, Matthew Whelihan
-
Patent number: 11884702Abstract: Methods are provided for isolation of immunoglobulin G (IgG) from plasma, where IgG is initially fractioned by salt precipitation, followed by successive ion exchange steps in which IgG appears in unbound, flow-through fractions of the ion exchange steps. Some embodiments employ successive anion exchange steps. Other embodiments employ an anion exchange step followed by application of flow-through of the anion exchange step to a cation exchange step, with IgG collected in flow-through fractions from the cation exchange step. IgG is collected at high yield (typically about 75% or greater) and high purity. Avoidance of binding and elution from chromatography media simplifies processing and scale up without sacrificing IgG quality or yield.Type: GrantFiled: December 22, 2021Date of Patent: January 30, 2024Assignee: Plasma Technologies, LLCInventors: Eugene Zurlo, Dennis Curtin, Klaus Peter Radtke, Ryan Dorfman, Matthew Whelihan
-
Patent number: 11732004Abstract: Compositions and methods are provided that simplify isolation of proteins of interest from serum or plasma. Finely divided silica or a similar lipid/lipoprotein binding solid is used in combination with a protein precipitating agent to generate a solution that includes the protein of interest and that can be applied to chromatography media without resulting in significant fouling of the media. The method is particularly suitable for isolation of immunoglobulin G.Type: GrantFiled: April 8, 2021Date of Patent: August 22, 2023Assignee: Plasma Technologies, LLCInventors: Eugene Zurlo, Dennis Curtin, Klaus Peter Radtke, Kurt L. Brillhart
-
Publication number: 20230129803Abstract: Systems and methods are described in which proteins are isolated from complex solution using successive chromatographic separations that retain the protein of interest in the flow-through. At least one of the chromatography media used is selected to be capable of interacting with both contaminants and the protein of interest, however capacity of this media is selected such that the protein of interest is displaced and remains in the flow-through.Type: ApplicationFiled: December 22, 2021Publication date: April 27, 2023Inventors: Eugene Zurlo, Dennis Curtin, Klaus Peter Radtke, Ryan Dorfman, Matthew Whelihan
-
Publication number: 20220402969Abstract: Methods of producing multiple protein products from blood-based materials including alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins are described herein. The inventive methods include steps of fractionation that utilize a combination of salt and organic solvent. Advantageously, the inventive methods are simple and produce alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins in high yields. The sequence of process steps can be selected to obtain multiple products from various in-process materials, such as supernatants, pastes, chromatography flow-though, and chromatography washes.Type: ApplicationFiled: August 24, 2022Publication date: December 22, 2022Inventors: Eugene Zurlo, Dennis Curtin, Klaus Peter Radtke
-
Publication number: 20220204556Abstract: Methods are provided for isolation of immunoglobulin G (IgG) from plasma, where IgG is initially fractioned by salt precipitation, followed by successive ion exchange steps in which IgG appears in unbound, flow-through fractions of the ion exchange steps. Some embodiments employ successive anion exchange steps. Other embodiments employ an anion exchange step followed by application of flow-through of the anion exchange step to a cation exchange step, with IgG collected in flow-through fractions from the cation exchange step. IgG is collected at high yield (typically about 75% or greater) and high purity. Avoidance of binding and elution from chromatography media simplifies processing and scale up without sacrificing IgG quality or yield.Type: ApplicationFiled: December 22, 2021Publication date: June 30, 2022Inventors: Eugene Zurlo, Dennis Curtin, Klaus Peter Radtke, Ryan Dorfman, Matthew Whelihan
-
Publication number: 20090232798Abstract: A method of treatment or prophylaxis of herpes infections and associated disease states by administration of compositions comprising immunoglobulins. Methods comprising intravenous and topical administration of immunoglobulins are provided.Type: ApplicationFiled: March 19, 2009Publication date: September 17, 2009Applicant: Talecris Biotherapeutics, Inc.Inventors: Ulrich Betz, Klaus-Peter Radtke
-
Publication number: 20060198848Abstract: A method of treatment or prophylaxis of herpes infections and associated disease states by administration of compositions comprising immunoglobulins. Methods comprising intravenous and topical administration of immunoglobulins are provided.Type: ApplicationFiled: March 3, 2006Publication date: September 7, 2006Inventors: Ulrich Betz, Klaus-Peter Radtke
-
Patent number: 6984492Abstract: A method of treatment or prophylaxis of herpes infections and associated disease states by administration of compositions comprising immunoglobulins. Methods comprising intravenous and topical administration of immunoglobulins are provided.Type: GrantFiled: September 5, 2003Date of Patent: January 10, 2006Assignee: Talecris Biotherapeutics, Inc.Inventors: Ulrich Betz, Klaus-Peter Radtke
-
Patent number: 6955917Abstract: An improved process for the purification of antibodies from human plasma or other sources is disclosed. The process involves suspension of the antibodies at pH 3.8 to 4.5 followed by addition of caprylic acid and a pH shift to pH 5.0 to 5.2. A precipitate of contaminating proteins, lipids and caprylate forms and is removed, while the majority of the antibodies remain in solution. Sodium caprylate is again added to a final concentration of not less than about 15 mM. This solution is incubated for 1 hour at 25° C. to effect viral inactivation. A precipitate (mainly caprylate) is removed and the clear solution is diluted with purified water to reduce ionic strength. Anion exchange chromatography using two different resins is utilized to obtain an exceptionally pure IgG with subclass distribution similar to the starting distribution. The method maximizes yield and produces a gamma globulin with greater than 99% purity. The resin columns used to obtain a high yield of IgG retain IgM and IgA.Type: GrantFiled: October 15, 2002Date of Patent: October 18, 2005Assignee: Bayer Healthcare LLCInventors: Patricia Alred, Scott A. Cook, Wytold R. Lebing, Douglas C. Lee, Hanns-Ingolf Paul, Klaus-Peter Radtke
-
Publication number: 20050053605Abstract: A method of treatment or prophylaxis of herpes infections and associated disease states by administration of compositions comprising immunoglobulins. Methods comprising intravenous and topical administration of immunoglobulins are provided.Type: ApplicationFiled: September 5, 2003Publication date: March 10, 2005Inventors: Ulrich Betz, Klaus-Peter Radtke
-
Publication number: 20030152966Abstract: An improved process for the purification of antibodies from human plasma or other sources is disclosed. The process involves suspension of the antibodies at pH 3.8 to 4.5 followed by addition of caprylic acid and a pH shift to pH 5.0 to 5.2. A precipitate of contaminating proteins, lipids and caprylate forms and is removed, while the majority of the antibodies remain in solution. Sodium caprylate is again added to a final concentration of not less than about 15 mM. This solution is incubated for 1 hour at 25° C. to effect viral inactivation. A precipitate (mainly caprylate) is removed and the clear solution is diluted with purified water to reduce ionic strength. Anion exchange chromatography using two different resins is utilized to obtain an exceptionally pure IgG with subclass distribution similar to the starting distribution. The method maximizes yield and produces a gamma globulin with greater than 99% purity. The resin columns used to obtain a high yield of IgG retain IgM and IgA.Type: ApplicationFiled: October 15, 2002Publication date: August 14, 2003Inventors: Patricia Alred, Scott A. Cook, Wytold R. Lebing, Douglas C. Lee, Hanns-Ingolf Paul, Klaus-Peter Radtke
-
Patent number: 6521226Abstract: The invention is directed to a method of decreasing atheroma formation in a mammal comprising administering a pharmaceutically effective amount of PON-1 or its functional equivalent to a patient in need thereof. Also included herein are pharmaceutical compositions, and a method for diagnosing predisposition to hypercholesterolemia by assessing the level of native circulating PON-1.Type: GrantFiled: March 25, 2002Date of Patent: February 18, 2003Assignee: Bayer CorporationInventor: Klaus-Peter Radtke
-
Publication number: 20030027759Abstract: The invention is directed to a method of decreasing atheroma formation in a mammal comprising administering a pharmaceutically effective amount of PON-1 or its functional equivalent to a patient in need thereof. Also included herein are pharmaceutical compositions, and a method for diagnosing predisposition to hypercholesterolemia by assessing the level of native circulating PON-1.Type: ApplicationFiled: March 25, 2002Publication date: February 6, 2003Inventor: Klaus-Peter Radtke
-
Patent number: 6391298Abstract: The invention is directed to a method of decreasing atheroma formation in a mammal comprising administering a pharmaceutically effective amount of PON-1 or its functional equivalent to a patient in need thereof. Also included herein are pharmaceutical compositions, and a method for diagnosing predisposition to hypercholesterolemia by assessing the level of native circulating PON-1.Type: GrantFiled: November 25, 1998Date of Patent: May 21, 2002Assignee: Bayer CorporationInventor: Klaus-Peter Radtke
-
Patent number: 5512449Abstract: A method and an agent for the functional determination of protein C inhibitor in body fluids are described, in which this fluid is incubated with a known amount of a plasminogen activator, fibrinogen and a sulfated carbohydrate, and the residual activity of the plasminogen activator is determined, and from this the amount of protein C inhibitor is determined.Type: GrantFiled: November 30, 1994Date of Patent: April 30, 1996Assignee: Behringwerke AktiengesellschaftInventors: Thomas Stief, Norbert Heimburger, Klaus-Peter Radtke
-
Patent number: 5234667Abstract: A centrifuge tube has elongated hollow vessel, and the vessel has a closed bottom end. A portion of the inner surface of the vessel is roughened near the closed bottom end, e.g., by micropitting the portion such that the solid pellet or precipitate that is separated from the supernatant of a specimen during centrifuging is retained on the roughened portion when the supernatant is drawn out of the tube subsequent to centrifuging. If desired, a sticky substance can be deposited on the roughened portion of the inner surface to further facilitate retention of the pellet on the roughened portion when the supernatant is drawn out of the tube subsequent to centrifuging.Type: GrantFiled: February 3, 1992Date of Patent: August 10, 1993Assignee: The Scripps Research InstituteInventors: Klaus-Peter Radtke, Arthur J. Robbins
-
Patent number: 5204256Abstract: A process for the purification of plasminogen activator inhibitor 2 (PAI-2) including the steps of preincubating a PAI-2-containing solution with a compound which cleaves disulfide linkages, mixing the solution with a water-soluble acridine or quinoline base to precipitate impurities in the solution, and separating the precipitated impurities to obtain PAI-2 in purified form.Type: GrantFiled: June 2, 1992Date of Patent: April 20, 1993Assignee: Behringwerke AktiengesellschaftInventors: Klaus-Peter Radtke, Norbert Heimburger, Karlheinz Wenz
-
Patent number: RE43655Abstract: An improved process for the purification of antibodies from human plasma or other sources is disclosed. The process involves suspension of the antibodies at pH 3.8 to 4.5 followed by addition of caprylic acid and a pH shift to pH 5.0 to 5.2. A precipitate of contaminating proteins, lipids and caprylate forms and is removed, while the majority of the antibodies remain in solution. Sodium caprylate is again added to a final concentration of not less than about 15 mM. This solution is incubated for 1 hour at 25° C. to affect viral inactivation. A precipitate (mainly caprylate) is removed and the clear solution is diluted with purified water to reduce ionic strength. Anion exchange chromatography using two different resins is utilized to obtain an exceptionally pure IgG with subclass distribution similar to the starting distribution. The method maximizes yield and produces a gamma globulin with greater than 99% purity. The resin columns used to obtain a high yield of IgG retain IgM and IgA.Type: GrantFiled: October 17, 2007Date of Patent: September 11, 2012Assignee: Bayer HealthCare LLCInventors: Wytold R. Lebing, Douglas C. Lee, Klaus-Peter Radtke, Scott A. Cook, Hanns-Ingolf Paul, Patricia Alred
-
Patent number: RE44558Abstract: An improved process for the purification of antibodies from human plasma or other sources is disclosed. The process involves suspension of the antibodies at pH 3.8 to 4.5 followed by addition of caprylic acid and a pH shift to pH 5.0 to 5.2. A precipitate of contaminating proteins, lipids and caprylate forms and is removed, while the majority of the antibodies remain in solution. Sodium caprylate is again added to a final concentration of not less than about 15 mM. This solution is incubated for 1 hour at 25° C. to effect viral inactivation. A precipitate (mainly caprylate) is removed and the clear solution is diluted with purified water to reduce ionic strength. Anion exchange chromatography using two different resins is utilized to obtain an exceptionally pure IgG with subclass distribution similar to the starting distribution. The method maximizes yield and produces a gamma globulin with greater than 99% purity. The resin columns used to obtain a high yield of IgG retain IgM and IgA.Type: GrantFiled: July 19, 2012Date of Patent: October 22, 2013Assignee: Bayer HealthCare LLCInventors: Patricia Alred, Scott A. Cook, Wytold R. Lebing, Douglas C. Lee, Hanns-Ingolf Paul, Klaus-Peter Radtke